52 / 74
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 2, March/April 2019
118
AFRICA
ence to oral anticoagulant and factors that influence the international
normalized ratio stability.
Rev Latino-Am Enfermagem
2011;
19
(1):
18–25.
6.
Corotto PS, McCarey MM, Adams S, Khazanie P, Whellan DJ. Heart
failure patient adherence: epidemiology, cause, and treatment.
Heart Fail
Clin
2013;
9
(1): 49–58. doi: 10.1016/j.hfc.2012.09.004.
7.
Riegel B. I forgot: memory and medication adherence in heart failure.
Circ Heart Fail
2016;
9
(12). pii: e003642
8.
LamWY, FrescoP.Medication adherencemeasures: an overview.
BioMed
Res Int
2015;
2015
: 217047,
http://dx.doi.org/10.1155/2015/217047.9.
Nguyen TM, La Caze A, Cottrell N. What are validated self-report
adherence scales really measuring? a systematic review.
Br J Clin
Pharmacol
2014;
7
(3): 427–445. doi: 10.1111/bcp.12194. PMCID:
PMC3952718.
10. Morisky DE, DiMatteo MR. Improving the measurement of self-
reported medication nonadherence: final response.
J Clin Epidem
2011;
64
(3): 255–257.
11. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive valid-
ity of a medication adherence measure in an outpatient setting.
J Clin
Hypertens
(Greenwich) 2008;
10
(5): 348–354.
12. Jankowska-Pola
ń
ska B, Chudiak A, Uchmanowicz I, Dudek K, Mazur
G. Selected factors affecting adherence in the pharmacological treat-
ment of arterial hypertension.
Patient Prefer Adherence
2017;
11
:
363–371. doi:10.2147/PPA.S127407.
13. Morisky DE, DiMatteo MR. Improving the measurement of self-
reported medication nonadherence: final response
. J Clin Epidem
2011;
64
: 258–263.
14. Culig J, Leppée M. From Morisky to Hill–Bone; self-reports scales for
measuring adherence to medication.
Coll Antropol
2014;
38
(1): 55–62.
15. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing
of the Hill–Bone compliance to high blood pressure therapy scale.
Prog
Cardiovasc Nurs
2000;
15
(3): 90–96. doi: 10.1111/j.1751-7117.2000.tb00.
16. Uchmanowicz I, Jankowska-Pola
ń
ska B, Chudiak A, Szyma
ń
ska-
Chabowska A, Mazur G. Psychometric evaluation of the Polish adap-
tation of the Hill–Bone Compliance to High Blood Pressure Therapy
Scale.
BMC Cardiovasc Disord
2016;
16
: 87. doi: 10.1186/s12872-016-
0270-y.
17. Ma C, Chen S, You L, Luo Z, Xing C. Development and psychometric
evaluation of the Treatment Adherence Questionnaire for Patients with
Hypertension.
J Adv Nurs
2012;
68
(6): 1402–1413. doi: 10.1111/j.1365-
2648.2011.05835.x.
18. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief
Medication Questionnaire: a tool for screening patient adherence and
barriers to adherence.
Patient Educ Couns
1999;
37
(2): 113–124.
19. Lahdenperä TS, Wright CC, Kyngäs HA. Development of a scale to
assess the compliance of hypertensive patients.
Int J Nurs Stud
2003;
40
(7): 677–684.
20. Fongwa MN, Nandy K, Yang Q, Hays RD. The facilitators of and
barriers to adherence to hypertension treatment scale.
J Cardiovasc Nurs
2015;
30
(6): 484–490. doi: 10.1097/JCN.0000000000000206.
21. Risser J, Jacobson TA, Kripalani S. Development and psychometric
evaluation of the Self- efficacy for Appropriate Medication Use Scale
(SEAMS) in low-literacy patients with chronic disease.
J Nurs Meas
2007;
15
(3): 203–219.
22. Patel SI, Cherington C, Scherber R,
et al
. Assessment of patient adher-
ence to direct oral anticoagulant vs warfarin therapy.
J Am Osteopath
Assoc
2017;
117
(1): 7–15. doi: 10.7556/jaoa.2017.002.
23. Jankowska-Pola
ń
ska B, Lomper K, Alberska L, Jaroch J, Dudek K,
Uchmanowicz I. Cognitive function and adherence to anticoagulation
treatment in patients with atrial fibrillation.
J Geriatr Cardiol
2016;
13
(7): 559–565. doi: 10.11909/j.issn.1671-5411.2016.07.006.
24. Castellucci LA, Shaw J, van der Salm K,
et al.
Self-reported adherence
to anticoagulation and its determinants using the Morisky medication
adherence scale.
Thromb Res
2015;
136
(4): 727–731. doi: 10.1016/j.
thromres.2015.07.007. Epub 2015 Jul 14.
25. Laliberté F, Bookhart BK, Nelson WW,
et al
. Impact of once-daily
versus twice-daily dosing frequency on adherence to chronic medica-
tions among patients with venous thromboembolism.
Patient
2013;
6
(3):
213–224. doi: 10.1007/s40271-013-0020-5.
26. Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J,
Duh MS. Impact of daily dosing frequency on adherence to chronic
medications among nonvalvular atrial fibrillation patients.
Adv Ther
2012;
29
(8): 675–690. doi: 10.1007/s12325-012-0040-x.
27. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabi-
gatran, and apixaban for stroke prevention in incident, treatment-naïve
nonvalvular atrial fibrillation.
J Manag Care Spec Pharm
2016;
22
(11):
1319–1329.
28. Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment
Scale (ACTS) in clinical trials: cross-cultural validation in venous
thromboembolism patients.
Health Qual Life Outcomes
2012;
10
: 120.
doi: 10.1186/1477-7525-10-120.
29. Prins MH, Bamber L, Cano SJ,
et al
. Patient-reported treatment satis-
faction with oral rivaroxaban versus standard therapy in the treatment
of pulmonary embolism; results from the EINSTEIN PE trial.
Thromb
Res
2015;
135
(2): 281–288. doi: 10.1016/j.thromres.2014.11.008.
30. Bamber L, Wang MY, Prins MH,
et al.
Patient-reported treatment satis-
faction with oral rivaroxaban versus standard therapy in the treatment
of acute symptomatic deep-vein thrombosis.
Thromb Haemost
2013;
110
(4): 732–741.
31. Meyer S, Frei CR, Daniels KR,
et al
. Impact of a new method of warfa-
rin management on patient satisfaction, time, and cost.
Pharmacotherapy
2013;
33
(11): 1147–1155. doi: 10.1002/phar.1344.
32. Carris NW, Hwang AY, Smith SM,
et al
. Patient satisfaction with
extended-interval warfarin monitoring.
J Thromb Thrombolysis
2016;
42
(4): 486–493. doi: 10.1007/s11239-016-1385-9.
33. Essers BA, Prins MH. Methods to measure treatment satisfaction in
patients with pulmonary embolismor deep venous thrombosis.
Curr Opin
Pulm Med
2010;
16
(5): 437–441. doi: 10.1097/MCP.0b013e32833bde2b.
34. Wild D, Murray M, Shakespeare A, Reaney M, von Maltzahn R.
Patient-reported treatment satisfaction measures for long-term antico-
agulant therapy.
Expert Rev Pharmacoecon Outcomes Res
2008;
8
(3):
291–299. doi: 10.1586/14737167.8.3.291.
35. Pelegrino FM, Dantas RA, Corbi IS, da Silva Carvalho AR, Schmidt
A, Pazin Filho AJ. Cross-cultural adaptation and psychometric proper-
ties of the Brazilian-Portuguese version of the Duke Anticoagulation
Satisfaction Scale.
J Clin Nurs
2012;
21
(17–18): 2509–2517. doi:
10.1111/j.1365-2702.2011.03869.x.
36. Samsa G, Matchar DB, Dolor RJ,
et al.
New instrument for measuring
anticoagulation- related quality of life: development and preliminary
validation.
Health Qual Life Outcomes
2004;
2
: 22.
37. Silva de Assis MC, Nascimento Cruz L, Zuchinali P, Rohde LE, Rejane
Rabelo E. Does treatment guided by vitamin K in the diet alter the qual-
ity of life of anticoagulated patients?
Nutr Hosp
2012;
27
(4): 1328–1333.
doi: 10.3305/nh.2012.27.4.5847.
38. Müller S, Kohlmann T, Wilke T. Validation of the Adherence Barriers
Questionnaire – an instrument for identifying potential risk factors asso-
ciated with medication-related non-adherence.
BMC Health Services
Res
2015;
15
: 153. doi:10.1186/s12913-015-0809-0.
39. Prins MH, Marrel A, Carita P,
et al
. Multinational development of a
questionnaire assessing patient satisfaction with anticoagulant treat-